Monte Rosa Therapeutics
@monterosatx.com
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more.
CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study.
Read the full data release here: bit.ly/4pxGtWz
Read the full data release here: bit.ly/4pxGtWz
January 12, 2026 at 3:15 PM
CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study.
Read the full data release here: bit.ly/4pxGtWz
Read the full data release here: bit.ly/4pxGtWz
Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. bit.ly/4pxGtWz
January 7, 2026 at 4:27 PM
Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. bit.ly/4pxGtWz
Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6.
January 7, 2026 at 12:14 PM
Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6.
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
January 6, 2026 at 1:48 PM
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
December 22, 2025 at 1:10 PM
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.
December 18, 2025 at 12:59 PM
This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.
Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC.
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
December 16, 2025 at 12:31 PM
Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC.
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
We will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, December 16 to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients.
Access the webcast here: bit.ly/3KSVjbQ
Access the webcast here: bit.ly/3KSVjbQ
December 15, 2025 at 9:36 PM
We will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, December 16 to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients.
Access the webcast here: bit.ly/3KSVjbQ
Access the webcast here: bit.ly/3KSVjbQ
Our colleagues break down the work behind this year’s Science Magazine cover story and what it means for the future of molecular glue degrader (MGD) development:
bit.ly/3KvGUlL
bit.ly/3KvGUlL
December 10, 2025 at 1:38 PM
Our colleagues break down the work behind this year’s Science Magazine cover story and what it means for the future of molecular glue degrader (MGD) development:
bit.ly/3KvGUlL
bit.ly/3KvGUlL
Our invited review in @cp-trendsbiotech.bsky.social is now out in print. The piece explores how machine learning can predict de novo protein–protein interactions, including those induced by our molecular glues.
Kudos to the team for their leadership in this rapidly expanding field: bit.ly/4plKI8g
Kudos to the team for their leadership in this rapidly expanding field: bit.ly/4plKI8g
December 3, 2025 at 4:19 PM
Our invited review in @cp-trendsbiotech.bsky.social is now out in print. The piece explores how machine learning can predict de novo protein–protein interactions, including those induced by our molecular glues.
Kudos to the team for their leadership in this rapidly expanding field: bit.ly/4plKI8g
Kudos to the team for their leadership in this rapidly expanding field: bit.ly/4plKI8g
Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference, where he’ll share insights on Monte Rosa and the progress of our molecular glue degraders.
To register: bit.ly/44I2dam
To register: bit.ly/44I2dam
December 2, 2025 at 1:12 PM
Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference, where he’ll share insights on Monte Rosa and the progress of our molecular glue degraders.
To register: bit.ly/44I2dam
To register: bit.ly/44I2dam
Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism.
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
November 19, 2025 at 3:28 PM
Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism.
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk
ICYMI, this year we were thrilled to be named “Biotech of the Year” at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting, and congratulations to our entire team.
November 18, 2025 at 12:59 PM
ICYMI, this year we were thrilled to be named “Biotech of the Year” at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting, and congratulations to our entire team.
In London for the Jefferies Global Healthcare Conference, or following along virtually? Join our CEO, Markus Warmuth, for a fireside chat as he reviews the latest on our pipeline programs.
Register or view the webcast: bit.ly/3X0oso4
Register or view the webcast: bit.ly/3X0oso4
November 17, 2025 at 1:09 PM
In London for the Jefferies Global Healthcare Conference, or following along virtually? Join our CEO, Markus Warmuth, for a fireside chat as he reviews the latest on our pipeline programs.
Register or view the webcast: bit.ly/3X0oso4
Register or view the webcast: bit.ly/3X0oso4
Our CMO, Filip Janku, will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio.
Register or view the webcast: bit.ly/4p8Inx1
Register or view the webcast: bit.ly/4p8Inx1
November 13, 2025 at 1:16 PM
Our CMO, Filip Janku, will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio.
Register or view the webcast: bit.ly/4p8Inx1
Register or view the webcast: bit.ly/4p8Inx1
ICYMI: We presented preclinical data at #AHA2025 showing that degrading NEK7 to modulate the NLRP3 inflammasome offers a novel, differentiated approach with potential in cardiovascular and cardiometabolic diseases.
Learn more: bit.ly/3XjONNQ
Learn more: bit.ly/3XjONNQ
November 11, 2025 at 1:00 PM
ICYMI: We presented preclinical data at #AHA2025 showing that degrading NEK7 to modulate the NLRP3 inflammasome offers a novel, differentiated approach with potential in cardiovascular and cardiometabolic diseases.
Learn more: bit.ly/3XjONNQ
Learn more: bit.ly/3XjONNQ
CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference.
To register: bit.ly/4qIpZwq
To register: bit.ly/4qIpZwq
November 10, 2025 at 1:00 PM
CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference.
To register: bit.ly/4qIpZwq
To register: bit.ly/4qIpZwq
Today, we present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome at AHA Scientific Sessions 2025.
Learn more: bit.ly/43SJQiF
#AHA2025
Learn more: bit.ly/43SJQiF
#AHA2025
November 8, 2025 at 4:38 PM
Today, we present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome at AHA Scientific Sessions 2025.
Learn more: bit.ly/43SJQiF
#AHA2025
Learn more: bit.ly/43SJQiF
#AHA2025
Today, we report financial results and business highlights for the third quarter 2025. Read more: bit.ly/43f5vBo
November 6, 2025 at 12:23 PM
Today, we report financial results and business highlights for the third quarter 2025. Read more: bit.ly/43f5vBo
ICYMI: our team presented data at #ACR25 showing MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology in a preclinical autoimmune model. CSO Sharon Townson shares perspective on the significance of these findings.
View the poster: bit.ly/3L955q7
View the poster: bit.ly/3L955q7
October 27, 2025 at 12:04 PM
ICYMI: our team presented data at #ACR25 showing MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology in a preclinical autoimmune model. CSO Sharon Townson shares perspective on the significance of these findings.
View the poster: bit.ly/3L955q7
View the poster: bit.ly/3L955q7
At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases.
Read the full press release here: bit.ly/4o7koyf
Read the full press release here: bit.ly/4o7koyf
October 24, 2025 at 11:04 AM
At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases.
Read the full press release here: bit.ly/4o7koyf
Read the full press release here: bit.ly/4o7koyf
Proud to be recognized among the “Six Targeted Protein Degrader Companies to Watch” by @clarivatelsh.bsky.social.
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
October 10, 2025 at 12:03 PM
Proud to be recognized among the “Six Targeted Protein Degrader Companies to Watch” by @clarivatelsh.bsky.social.
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
Adam Cartwright presents preclinical data today at #ECTRIMS2025 suggesting MRT-6160, a first-in-class VAV1-directed MGD, has the potential to benefit patients with neuroinflammatory diseases as well as other T- and B-cell immune-mediated conditions: bit.ly/3KEi7vf
September 25, 2025 at 11:14 AM
Adam Cartwright presents preclinical data today at #ECTRIMS2025 suggesting MRT-6160, a first-in-class VAV1-directed MGD, has the potential to benefit patients with neuroinflammatory diseases as well as other T- and B-cell immune-mediated conditions: bit.ly/3KEi7vf
David Wild of In Vivo had an insightful conversation with our CEO, Markus Warmuth, and CDIO, John Castle, about the past, present, and future of Monte Rosa, and the broad, growing potential of molecular glues. Read more [note that content is paywalled]: bit.ly/4gEiIJB
September 24, 2025 at 1:15 PM
David Wild of In Vivo had an insightful conversation with our CEO, Markus Warmuth, and CDIO, John Castle, about the past, present, and future of Monte Rosa, and the broad, growing potential of molecular glues. Read more [note that content is paywalled]: bit.ly/4gEiIJB
This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs.
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
September 16, 2025 at 12:02 PM
This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs.
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
CEO Markus Warmuth comments: bit.ly/3Vl0yTg